Source
Study design (if review, criteria of inclusion for studies)
Randomised parallel group trial
Participants
Mean age 10.7 years, range 6 years to 15 years n = 56 CF Females = 30 CF Males = 26
Interventions
Mistabron 20% 3 ml BD for 8 weeks versus HS 7% 3 ml BD for 8 weeks. No reported pre-treatment
Outcome measures
PEFR, FVC, V max 50% VC, RV/TLC
Main results
No significant changes were found in five patients with no measurable sputum production. The inhalations were given after physiotherapy and were well tolerated. There were no significant side effects.
Authors' conclusions
The results suggest that Mistabron has a beneficial therapeutic effect unrelated to its high osmolality, and the intermittent inhalation of Mistabron may have a role in the treatment of selected patients with cystic fibrosis.